Table 1.
Clinical profile of the ziv-aflibercept study
| Patient number | Age | Race gender | Initial vision | Final vision | Initial CMT in micron | CMT 1 week after injection | Height of RPE detachment (initial to final, μ) | Subretinal fluid | Prior therapies | Systemic disease |
|---|---|---|---|---|---|---|---|---|---|---|
| Case 1 (AMD) | 80 | Caucasian Male | 20/800 | 20/150 | 331 | 255 | 833–500 | Yes | No | No |
| Case 2 (AMD) | 89 | Caucasian Female | 20/100 | 20/60 | 748 | 473 | 1040–833 | Yes (minimal) | 11 bevacizumab/ 1 ranibizumab over 7.5 years | HTN; CAD |
| Case 3 (AMD) | 84 | Caucasian Male | 20/800 | 20/200 | 213 | 181 | 271–90 | Yes (minimal) | 5 bevacizumab over 14 months | DM; CAD; smoker |
| Case 4 (AMD) | 86 | Caucasian Male | 20/400 | 20/200 | 372 | 347 | 189–170 | Yes (minimal) | 4 bevacizumab over 14 months | HTN |
| Case 5 (diabetic maculopathy) | 69 | Caucasian Male | 20/800 | 20/100 | 508 | 443 | None | Yes | None | DM |
| Case 6 (diabetic maculopathy) | 61 | Caucasian Male | 20/800 | 20/200 | 720 | 368 | None | Yes (minimal) | Ranibizumab 2 Bevacizumab 1 | DM |
AMD, age-related macular degeneration; CAD, coronary artery disease; CMT, central macular thickness; DM, diabetes mellitus; HTN, systemic hypertension.